Evidence map›Paper›PMID 37901538›Full record

ArticleACS omega2023

Synthesis and Antitumor Activity of Brominated-Ormeloxifene (Br-ORM) against Cervical Cancer.

Mohammed Sikander, Shabnam Malik, John Apraku, Sonam Kumari, Parvez Khan, Hassan Mandil, Aditya Ganju, Bhavin Chauhan, Maria C Bell, Man Mohan Singh and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Mohammed SikanderDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States.
Shabnam MalikDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States.
John AprakuSouth Dakota State University, Brookings, South Dakota 57007-2201, United States.
Sonam KumariUniversity of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Parvez KhanJamia Millia Islamia University, New Delhi 110025, India.ORCID https://orcid.org/0000-0002-8566-0248
Hassan MandilUniversity of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Aditya GanjuUniversity of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Bhavin ChauhanUniversity of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Maria C BellSanford Health, Sanford Gynecologic Oncology Clinic, Sioux Falls, South Dakota 57104, United States.
Man Mohan SinghEndocrinology Division, CSIR-Central Drug Research Institute, Lucknow 226001, India.
Sheema KhanDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States.
Murali M YallapuDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States.ORCID https://orcid.org/0000-0002-0073-8828
Fathi T HalaweishSouth Dakota State University, Brookings, South Dakota 57007-2201, United States.
Meena JaggiDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States.
Subhash C ChauhanDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States.ORCID https://orcid.org/0000-0002-3347-5120
University of Tennessee Health Science Center · USSouth Dakota State University · USCentral Drug Research Institute · INJamia Millia Islamia · INMemorial Sloan Kettering Cancer Center · USNational Institutes of Health · USSanford Health · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
MUC13 Mucin in Colorectal Cancer Health DisparityR01CA204552 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2020
$1.7M
Development of Targeted Nanotechnology Platform for Pancreatic CancerR01CA206069 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
Targeted Nanotherapy for Pancreatic CancerR01CA210192 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204552NCI NIH HHS R01 CA206069NCI NIH HHS R01 CA210192
6 · The paper itself

Abstract

Aberrant regulation of β-catenin signaling is strongly linked with cancer proliferation, invasion, migration, and metastasis, thus, small molecules that can inhibit this pathway might have great clinical significance. Our molecular modeling studies suggest that ormeloxifene (ORM), a triphenylethylene molecule that docks with β-catenin, and its brominated analogue (Br-ORM) bind more effectively with relatively less energy (-7.6 kcal/mol) to the active site of β-catenin as compared to parent ORM. Herein, we report the synthesis and characterization of a Br-ORM by NMR and FTIR, as well as its anticancer activity in cervical cancer models. Br-ORM treatment effectively inhibited tumorigenic features (cell proliferation and colony-forming ability,

Identifiers

PMID37901538
PMCPMC10601051
OpenAlexW4387568759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.